Tumor regression grade of the primary tumor (TRG-PT) and residual lymph node metastasis have been pathologically determined in esophageal squamous cell carcinoma (ESCC) patients who had received neoadjuvant chemotherapy (nCT) followed by surgery; however, TRG of the metastatic tumor involving lymph nodes (LN) has not yet been determined. The aim of the present study was to clarify the impact of TRG on the prognosis of ESCC patients. ESCC patients (n = 110) who had received nCT followed by surgery were enrolled. Dissected LN were classified into 2 categories: plausible positive metastatic LN (pp-MLN) where viable and/or degenerated ESCC cells and/or tissue modifications were observed, and non-metastatic LN (non-MLN) where neither of them was observed. We defined nCT-effective rate (CER) as the ratio of the number of pp-MLN that showed tumor regression to the total number of pp-MLN, and divided CER into low-CER (LCER; ≥0% and <50%) and high-CER (HCER; ≥50% and ≤100%). Relationships between CER and clinicopathological factors including prognosis were then examined. Multivariate analyses of 110 patients indicated that ypT3-4 (P = .023, HR; 2.551), positive venous infiltration (P = .006, HR; 3.526), and LCER (P = .033, HR; 1.922) were independently associated with shorter recurrence-free survival (RFS). Multivariate analyses of 43 patients with grade 0 TRG-PT showed that ypT3-4 (P = .033, HR; 3.397) and LCER (P = .008, HR; 3.543) were independently associated with shorter RFS. This study showed that CER was one of the prognostic factors for ESCC patients who had received nCT followed by surgery.
prognostic factor, whereas residual LNM is a negative prognostic factor. 4 Neoadjuvant chemotherapy followed by surgery has been the standard therapy for breast cancer patients, with the aim of preserving breast organ. 5 Therefore, lymph node tissue modified by nCT undergoes pathological examination. Not only TRG-PT but also TRG-LN involved in the metastatic tumor has been routinely subjected to pathological examination, because TRG of primary and metastatic tumors has been implicated in predicting prognosis. [6] [7] [8] No residual tumor in ALN after nCT is well known to be a better prognostic factor, even in breast cancer patients who still have residual tumor at the primary site. 7 In contrast, regarding patients with ESCC who underwent nCRT or nCT using an anti-cancer effective regimen, residual LNM remains one of the poor prognostic factors. It suggests that it may be necessary for pathologists to determine the TRG of both primary and metastatic tumors involving LN in ESCC patients as well as in breast cancer patients who underwent nCT. It remains unknown whether TRG-PT or TRG-LN is associated with prognosis in ESCC patients.
The aim of the present study was to clarify the significance of TRG-LN as a prognostic factor in ESCC patients who had undergone nCT followed by surgery.
| PATIENTS AND METHODS

| Patients
Patients with locally advanced esophageal cancer who had undergone a combination therapy of nCT followed by surgery at the
National Cancer Center Hospital East between January 2008 and
March 2013 were enrolled. Eligibility criteria were as follows: (i) patients pathologically diagnosed using biopsy specimens, with squamous cell carcinoma prior to receiving any nCT; (ii) patients who underwent total or subtotal thoracic esophagectomy with regional lymph node dissection after nCT; (iii) patients whose performance status according to ECOG was 0-1; and (iv) patients whose dissected LN included at least 1 pp-MLN where viable and/or degenerated ESCC cells and/or tissue modifications. Patients who received macroscopically incomplete resection after nCT or died in hospital post-surgery were excluded from this study. However, patients who
were not able to receive a scheduled complete course of nCT were included. Consequently, 110 ESCC patients were enrolled in the study. Clinical staging before nCT was determined according to UICC-TNM classification (7th edition), 9 based on endoscopic findings and CECT. This study protocol was approved by the institutional review board of the National Cancer Center (2014-357).
| Neoadjuvant chemotherapy
The regimen of nCT was either 2 courses of CF, 3 or 3 courses of DCF. Each course was given every 3 weeks. All patients were scheduled to receive endoscopic examination and CECT after each course of the above chemotherapy for evaluating the therapeutic effect.
The patients underwent surgery after interrupting the course of nCT. Patients who did not respond to nCT or who presented with severe toxicity attributable to the nCT were included in this study. 
| Histopathological examinations
| TRG of metastatic lymph nodes
We newly determined TRG-LN in the present study as following 5 steps ( Figure S1 ). 
3.
In each patient, the number of all pp-MLN and pp-MLN with grades 1a, 1b, 2, and 3 were counted.
4.
The ratio of the number of pp-MLN that were categorized as grades 1a, 1b, 2, and 3 regarding TRG-LN to all pp-MLN (categorized as grades 0, 1a, 1b, 2, and 3 regarding TRG-LN) was calculated. We defined the ratio as the CER.
5.
We classified CER into two categories: LCER (low rate, ≥0% and <50%) or HCER (high rate, ≥50% and ≤100%). We determined total TRG-LN evaluation for each patient based on the definition of CER (LCER or HCER), as described above. In addition, we determined the highest or the lowest TRG-LN grades of pp-MLN in each patient, and examined relationships between RFS, and the highest TRG-LN grade or the lowest TRG-LN grade.
| Statistical analysis
Recurrence-free survival curves were estimated using the KaplanMeier method and were compared using the log-rank test. RFS was 
| Prognostic factors in univariate and multivariate analysis
Univariate analysis indicated that ypT3-4 (vs ypT0-2, HR; 4.553, P < .001), positive venous infiltration (vs negative, HR; 7.222, P < .001), grade 0 TRG-PT (vs grades 1a, 1b, 2, and 3 TRG-PT, HR;
2.228, P = .004), and LCER (vs HCER, HR; 2.367, P = .002) were poor prognostic factors for RFS (Table 2) . Consequently, of the variables with a P-value <. For patients with grade 0 TRG-PT, univariate analyses showed that the ypT factor (ypT3-4), venous infiltration, and LCER were predictors of a shorter RFS (Table 3 ). Multivariate analysis showed that ypT3-4 (vs ypT0-2, HR; 3.397, P = .033) and LCER (vs HCER, HR;
3.543, P = .008) were predictors of a shorter RFS. Patients with grade 0 TRG-PT and LCER had shorter RFS rates, and there was little difference between RFS rates of patients with grade 0 TRG-PT and HCER, and patients with grades 1a-3, regardless of the CER ( Figure S3 ).
| Relationship between RFS, and TRG-PT or CER in patients with ypStage II or III
In cases of dividing the patients with ypStage III into 2 groups, including the patients with grade 0 TRG-PT and the patients with grades 1a-3 TRG-PT, the latter patients were shown to have significantly longer RFS compared with those of the former patients (P = .0015), implying that TRG-PT may have an impact on RFS (Figure S4A) . In contrast, the same analysis in patients with ypStage II did not show any significant difference between the patients with grades 1a-3 TRG-PT and those with grade 0 TRG-PT (P = .91) (Figure S4A ). This might be attributed to the small sample size of the patients with ypStage II (n = 25).
In cases of dividing the patients with ypStage III into 2 groups, including the patients with HCER and the patients with LCER, the former patients were shown to have significantly longer RFS compared with those of the latter patients (P = .020), implying that CER may have an impact on RFS ( Figure S4B ). In contrast, the same analysis in patients with ypStage II did not show any significant difference between the patients with HCER and those with LCER (P = 0.17) ( Figure S4B ). This might be attributed to the small sample size of the patients with ypStage II (n = 25). However, the number of patients with ypStage I or IV was so small that it was impossible to conduct the same statistical analyses as described above (Table S2) .
F I G U R E 2
Recurrence-free survival (RFS) and overall survival (OS) curves according to tumor regression grade of primary tumor (TRG-PT) or chemotherapy-effective rate (CER). A, RFS curves according to TRG-PT including grades 0, 1a, 1b, 2, and 3. B, RFS curves of the 2 groups of grade 0 TRG-PT and grades 1a, 1b, 2, and 3. There was a significant difference between the grade 0 group and the grades 1a, 1b, 2, and 3 group (P = .003). C, RFS curves of low CER (LCER) and high CER (HCER). There was a significant difference in RFS between LCER and HCER groups (P = .0014). D, OS curves of LCER and HCER. There was a significant difference in OS between LCER and HCER groups (P = .0012)
Lymph node metastasis is a critical negative prognostic factor in ESCC patients. Some previous investigators attempted to classify ESCC patients who received neoadjuvant therapy including nCT and nCRT followed by surgery, according to a combination of TRG-PT and residual LNM; however, these classifiers could not be used to divide patients with completely different prognoses. [11] [12] [13] [14] [15] [16] It is possible that TRG-PT reflects the neoadjuvant therapeutic effect on the primary tumor, whereas ypN stage reflects only the residual tumor in LN after neoadjuvant therapy. In other words, ypN stage cannot reflect the degree of the therapeutic effect on tumor cells in metastatic LN, according to nCT. This suggests that it might be necessary to evaluate the degree of tumor regression in metastatic LN; therefore, we created a new category, CER, which could reflect the degree of the neoadjuvant therapeutic effect. In the present study, F I G U R E 3 Recurrence-free survival (RFS) and overall survival (OS) curves of low chemotherapy-effective rate (LCER) and high chemotherapy-effective rate (HCER) groups in the grade 0 tumor regression grade of primary tumor (TRG-PT) group and in the grades 1a, 1b, 2, and 3 TRG-PT group. A, RFS curves of LCER and HCER groups in patients with grade 0 TRG-PT. There was a significant difference between LCER and HCER groups (P = .0028). B, RFS curves of LCER and HCER groups in patients with grades 1a, 1b, 2, and 3 TRG-PT. There was not a significant difference between LCER and HCER groups (P = .476). C, OS curves of LCER and HCER groups in patients with grade 0 TRG-PT. There was a significant difference between the LCER and HCER groups (P = .015). D, OS curves of LCER and HCER groups in patients with grades 1a, 1b, 2, and 3 TRG-PT. There was not a significant difference between the LCER and HCER groups (P = .196) CER was shown to be an independent predictor for a poor prognosis, especially in patients with grade 0 TRG-PT. This suggested that the chemotherapeutic effect in LN might be a better prognostic factor, even with residual tumor at the primary site as well as in breast cancer. 7 In the present study, CER could be used to identify the patient group with the worst prognosis that was not selected by only TRG-PT as one of the classifiers. That is, patients with grade 0 TRG-PT and residual LNM with an LCER had a worse prognosis. Currently, nCT or nCRT followed by surgery is one of the standard treatments in Japan based on results from some clinical trials comparing the therapeutic effect of only surgery with that of surgery followed by adjuvant CT or CRT. However, trial results showed that the 5-year overall survival and progression-free survival was not so high (55% and 44%). 3 Therefore, a new therapeutic strategy needs to be established for patients who do not respond to neoadjuvant therapy. As a first step, candidate patients requiring a new therapeutic strategy should be narrowed down by using our new categories, for example, CER.
In the present study, we examined all LN dissected together with the primary resected tumor, according to the same classification as that of TRG-PT, and could set the CER for LN as an independent prognostic factor. Because our study was retrospective in nature, and enrolled patients from one institution only, it will be necessary to carry out a validation study in another cohort.
In conclusion, our study showed that accurate evaluation of TRG-LN under the microscope, in addition to TRG-PT, allowed us to predict the prognosis of patients who had received nCT followed by surgery.
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